A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus

A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus

Systemic lupus erythematosus is a chronic inflammatory disease, in which treatment is still limited due to suboptimal efficacy and toxicities associated with the available therapies. JAK kinases are well known to play an important role in systemic lupus erythematous. There is growing evidence that R...

Full description

Bibliographic Details
Main Authors: Maria Dulak-Lis, Anna Bujak, Kamila Gala, Martyna Banach, Urszula Kędzierska, Joanna Miszkiel, Joanna Hucz-Kalitowska, Michał Mroczkiewicz, Bartosz Stypik, Krzysztof Szymczak, Paweł Gunerka, Krzysztof Dubiel, Beata M. Zygmunt, Maciej Wieczorek, Jerzy S. Pieczykolan
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:Journal of Pharmacological Sciences
Subjects:
JAK3
JAK1
Lupus
ROCK
Nephritis
Online Access:http://www.sciencedirect.com/science/article/pii/S134786132100013X

Internet

http://www.sciencedirect.com/science/article/pii/S134786132100013X

Similar Items